{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:50:42Z","timestamp":1784019042115,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017600","name":"Science Research Foundation of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017600","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020777","name":"Zhejiang Pharmaceutical Association","doi-asserted-by":"publisher","award":["2019ZYY22"],"award-info":[{"award-number":["2019ZYY22"]}],"id":[{"id":"10.13039\/501100020777","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020777","name":"Zhejiang Pharmaceutical Association","doi-asserted-by":"publisher","award":["2021ZYY22"],"award-info":[{"award-number":["2021ZYY22"]}],"id":[{"id":"10.13039\/501100020777","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2019KY473"],"award-info":[{"award-number":["2019KY473"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.biopha.2022.114015","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T05:25:45Z","timestamp":1668403545000},"page":"114015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pirfenidone inhibits stromal collagen deposition and improves intra-tumoral delivery and antitumor efficacy of Pegylated liposomal doxorubicin"],"prefix":"10.1016","volume":"157","author":[{"given":"Tiantian","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaomei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanzhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6422-6461","authenticated-orcid":false,"given":"Zheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2022.114015_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.114015_bib2","unstructured":"G. Ayala, J.A. Tuxhorn, T.M. Wheeler, A. Frolov, P.T. Scardino, M. Ohori, M. Wheeler, J. Spitler, D.R. Rowley, Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer, Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res., vol. 9(no. 13), 2003, pp. 4792\u2013801."},{"issue":"1","key":"10.1016\/j.biopha.2022.114015_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1042\/BST20160387","article-title":"Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis","volume":"45","author":"Erdogan","year":"2017","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.biopha.2022.114015_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2014.00062","article-title":"Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment","volume":"4","author":"Augsten","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2022.114015_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2016.09.014","article-title":"Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system","volume":"241","author":"Chen","year":"2016","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"7","key":"10.1016\/j.biopha.2022.114015_bib6","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.biopha.2022.114015_bib7","first-page":"2497","article-title":"Role of extracellular matrix assembly in interstitial transport in solid tumors","volume":"60","author":"Netti","year":"2000","journal-title":"Cancer Res."},{"issue":"Pt A","key":"10.1016\/j.biopha.2022.114015_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2022.114015_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.apsb.2019.01.011","article-title":"Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application","volume":"9","author":"Xia","year":"2019","journal-title":"Acta Pharmaceut. Sin. B"},{"key":"10.1016\/j.biopha.2022.114015_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2016.04.028","article-title":"Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin","volume":"232","author":"Petersen","year":"2016","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"4","key":"10.1016\/j.biopha.2022.114015_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41401-018-0038-2","article-title":"Asiatic acid enhances intratumor delivery and the antitumor effect of pegylated liposomal doxorubicin by reducing tumor-stroma collagen","volume":"40","author":"Fang","year":"2019","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.biopha.2022.114015_bib12","first-page":"2007363","article-title":"Strategies for delivering nanoparticles across tumor blood vessels","author":"Sheth","year":"2020","journal-title":"Adv. Funct. Mater."},{"issue":"4","key":"10.1016\/j.biopha.2022.114015_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2022.114015_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3892\/ijmm.2021.4958","article-title":"MicroRNA\u2011133b alleviates doxorubicin\u2011induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2","volume":"48","author":"Li","year":"2021","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.114015_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13104-018-3260-6","article-title":"Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice","volume":"11","author":"Stark","year":"2018","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.biopha.2022.114015_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist. Updates"},{"issue":"146","key":"10.1016\/j.biopha.2022.114015_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0057-2017","article-title":"Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis","volume":"26","author":"Lancaster","year":"2017","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2022.114015_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.biopha.2022.114015_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of pirfenidone on proliferation, TGF-\u03b2-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","volume":"58","author":"Conte","year":"2014","journal-title":"Eur. J. Pharmaceut. Sci.: Off. J. Eur. Fed. Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2022.114015_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","article-title":"Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt\/GSK-3\u03b2\/\u03b2-catenin and TGF-\u03b21\/Smad2\/3 signaling pathways","volume":"26","author":"Lv","year":"2020","journal-title":"Mol. Med."},{"issue":"18","key":"10.1016\/j.biopha.2022.114015_bib21","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2017-01-758854","article-title":"Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-\u03b2 production","volume":"129","author":"Du","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biopha.2022.114015_bib22","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","article-title":"Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial","volume":"27","author":"Lewis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.114015_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104694","article-title":"Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence","volume":"155","author":"Aimo","year":"2020","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.biopha.2022.114015_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-003-0703-z","article-title":"Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats","volume":"53","author":"Giri","year":"2004","journal-title":"Cancer Chemother. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2022.114015_bib25","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1158\/0008-5472.CAN-12-3180","article-title":"Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells","volume":"73","author":"Kozono","year":"2013","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.114015_bib26","doi-asserted-by":"crossref","first-page":"10070","DOI":"10.1038\/s41598-018-28297-x","article-title":"Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo","volume":"8","author":"Li","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2022.114015_bib27","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1039\/D0BM01878C","article-title":"On-demand responsive nanoplatform mediated targeting of CAFs and down-regulating mtROS-PYK2 signaling for antitumor metastasis","volume":"9","author":"Zuo","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biopha.2022.114015_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fphar.2020.00483","article-title":"Hepatoprotective and anti-oxidative effects of total flavonoids from Qu Zhi Qiao (Fruit of Citrus paradisi cv.Changshanhuyou) on nonalcoholic steatohepatitis in vivo and in vitro through Nrf2-ARE signaling pathway","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2022.114015_bib29","first-page":"12101","article-title":"Hyaluronan synthase 2 overexpression is correlated with the tumorigenesis and metastasis of human breast cancer","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"7","key":"10.1016\/j.biopha.2022.114015_bib30","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1111\/cas.14070","article-title":"Hyaluronic acid synthase 2 promotes malignant phenotypes of colorectal cancer cells through transforming growth factor beta signaling","volume":"110","author":"Kim","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2022.114015_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.biopha.2022.114015_bib32","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1158\/1078-0432.CCR-17-3284","article-title":"Parallel accumulation of tumor hyaluronan, collagen, and other drivers of tumor progression","volume":"24","author":"Li","year":"2018","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2022.114015_bib33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ejps.2011.09.006","article-title":"Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy","volume":"45","author":"Gabizon","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2022.114015_bib34","first-page":"88","article-title":"Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144","volume":"8","author":"Dy","year":"2009","journal-title":"Clin. Colorectal Cancer"},{"issue":"38","key":"10.1016\/j.biopha.2022.114015_bib35","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"15","key":"10.1016\/j.biopha.2022.114015_bib36","doi-asserted-by":"crossref","first-page":"24506","DOI":"10.18632\/oncotarget.15534","article-title":"Pirfenidone normalizes the tumor microenvironment to improve chemotherapy","volume":"8","author":"Polydorou","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2022.114015_bib37","doi-asserted-by":"crossref","first-page":"1824631","DOI":"10.1080\/2162402X.2020.1824631","article-title":"Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice","volume":"9","author":"Qin","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2022.114015_bib38","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ebiom.2019.11.011","article-title":"Ethanol promotes alcohol-related colorectal cancer metastasis via the TGF-\u03b2\/RUNX3\/Snail axis by inducing TGF-\u03b21 upregulation and RUNX3 cytoplasmic mislocalization","volume":"50","author":"Zheng","year":"2019","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.biopha.2022.114015_bib39","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1021\/acsami.5b11619","article-title":"An MMP-2 responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer","volume":"8","author":"Ji","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"6","key":"10.1016\/j.biopha.2022.114015_bib40","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7150\/ijms.43238","article-title":"The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-\u03b2 and MMP-1","volume":"17","author":"Tao","year":"2020","journal-title":"Int. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2022.114015_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-003-0703-z","article-title":"Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats","volume":"53","author":"Giri","year":"2004","journal-title":"Cancer Chemother. Pharm."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:58:05Z","timestamp":1778241485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222014044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":41,"alternative-id":["S0753332222014044"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114015","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pirfenidone inhibits stromal collagen deposition and improves intra-tumoral delivery and antitumor efficacy of Pegylated liposomal doxorubicin","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114015"}}